DCs-CIK细胞免疫治疗联合化疗治疗晚期非小细胞肺癌的疗效观察  

DCs-CIK Immunotherapy Combined with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

作　　者：杨林珠[1] 洪志鹏[1] 余庆鹤[1] 唐理见 李国邦 

机构地区：[1]昆明医科大学第一附属医院胸外科,云南昆明650032

出　　处：《现代生物医学进展》2015年第31期6146-6149,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨树突状细胞(DCs)和细胞因子诱导的杀伤(CIK)细胞免疫治疗联合化疗对晚期非小细胞肺癌患者的治疗效果。方法:将我院2012年2月到2014年2月就诊的72例晚期非小细胞肺癌患者随机分为对照组(n=36,单纯化疗组)和实验组(n=36,DCs-CIK细胞免疫联合化疗组)。比较两组患者治疗后的疗效、治疗前后免疫功能,并运用Kamofsky(KPS)评分来评估两组患者治疗后生活质量的改善情况。结果:实验组的疾病控制率(DCR)77.78%显著高于对照组的52.78%(P<0.05)。治疗后实验组患者外周血CD3+、CD8+及NK细胞所占的比值较治疗前均上升显著(P<0.05);治疗后对照组患者外周血CD3+、CD8+及NK细胞所占的比值较治疗前下降显著(P<0.05)。治疗后实验组KPS评分提高率明显高于对照组(P<0.05)。结论:DCs-CIK细胞免疫联合化疗能够提高晚期非小细胞肺癌患者的DCR,且显著改善患者的免疫功能和生活质量。Objective： To investigate the efficacy of dendritic cells（DCs） and cytokine-induced killer（CIK） immunotherapy combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods： A total of 72 patients with advanced non-small cell lung cancer, who were admitted to in First Affiliated Hospital of Kunming Medical University from February 2012 to February 2014, were randomly divided into study group（n=36, treated with DCs-CIK immunotherapy combined with chemotherapy） and control group（n=36, treated with chemotherapy）. The efficacy after treatment and immune function before and after treatment of the two groups were compared, and the quality of life after treatment of the two groups was evaluated by Kamofsky（KPS） score. Results： Disease control rate（DCR）（77.78%） in the study group was significantly higher than that（52.78%） in the control group（P〉0.05）. The ratio of eripheral blood CD3^＋, CD8^＋and natural killer（NK） cells in the study group after treatment significantly increased than before treatment（P〈0.05）; the ratio of eripheral blood CD3^＋, CD8^＋and natural killer（NK） cells in the control group after treatment significantly decreased than before treatment（P〈0.05）. The rising rate of KPS score in the study group after treatment was significantly higher than that in the control group（P〈0.05）. Conclusion： DCs-CIK immunotherapy combined with chemotherapy can effectively enhance the disease control rate of patients with advanced non-small cell lung cancer and significantly improve immune function and the quality of life of the patients.

关 键 词：非小细胞肺癌 树突状细胞 杀伤细胞 免疫治疗 疗效 

分 类 号：R734.2[医药卫生—肿瘤]